Previous 10 | Next 10 |
New data demonstrate the potential impact of DecisionDx®-SCC test results to guide risk-aligned patient management plans and increase confidence in disease management decisions Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests ...
DecisionDx-Melanoma integrates a patient’s clinicopathologic factors with his/her tumor biology to provide precise, personalized risk estimates, including five-year melanoma-specific survival, recurrence-free survival and distant metastasis-free survival Castle Biosci...
Clinical workflow for MyPath ® Melanoma and DiffDx ® -Melanoma provides a framework for use of the tests in clinical practice to reduce uncertainty in diagnoses Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative t...
Castle’s three-year financial targets include anticipated total revenue of $255-$330 million and anticipated net operating cash flow positivity for the year ending December 31, 2025 During its Investor Day today, senior leaders of Castle Biosciences, Inc. (Nasdaq:...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received an AZBio Fast Lane Award from the Arizona Bioindustry Association (AZBio). “Castle Biosciences is working to transform ho...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at Bai...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will host an Investor Day on Sept. 20, 2022. Derek Maetzold, president and chief executive officer, Frank Stokes, chief financial officer, and other members of Castl...
Castle Biosciences, Inc. (CSTL) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of IR & Corporate Communications Derek Maetzold - Founder, President & CEO Frank Stokes - CFO Confer...
Shares of Castle Biosciences ( NASDAQ: CSTL ) rose 8.6% to $30.92 in Tuesday afternoon trading, after the medical diagnostic company reported Q2 results that beat estimates and revised its FY 2022 revenue guidance higher. Friendswood, Texas-based CSTL provides several me...
Castle Biosciences press release ( NASDAQ: CSTL ): Q2 GAAP EPS of -$0.06 beats by $0.70 . Revenue of $34.8M (+52.9% Y/Y) beats by $6.43M . Shares +2.7% AH. For further details see: Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...